Search
Enfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalThe first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Categories: Gene Products, env, env Gene Products, Human Immunodeficiency VirusEnlicitide
go.drugbank.com/drugs/DB22580ApprovedInvestigationalavailable to clear low-density lipoprotein cholesterol (LDL-C), thereby lowering circulating LDL-C levels. … (CORALreef Lipids), and by 59% in patients with HeFH (CORALreef HeFH), with comparable reductions in non-HDL-C and apolipoprotein B.
Fedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigational[A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]
Clobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809] … [L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.
Synonyms: Clobetasol propionate EInternational brands: Embeline EVercirnon
go.drugbank.com/drugs/DB15250InvestigationalIt is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). … Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD.
International brands: Traficet-ENEnoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalEnoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.
Products: LOVENOX 10.000 IE (100 mg)/1 ml Injektionslösung in einer Fertigspritze, LOVENOX 15.000 IE (150 mg)/1 ml Injektionslösung in einer FertigspritzeRiociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.
Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminateTucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalIt was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.